Breast cancer stage IV – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:02 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Breast cancer stage IV – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Restoring Immunotherapy Sensitivity in Advanced Triple Negative Breast Cancer Using Ceralasertib, Durvalumab, and Paclitaxel Albumin-Bound https://clinicaltrials.eu/trial/study-on-restoring-immunotherapy-sensitivity-in-advanced-triple-negative-breast-cancer-using-ceralasertib-durvalumab-and-paclitaxel-albumin-bound/ Wed, 29 Apr 2026 15:00:49 +0000 https://clinicaltrials.eu/trial/study-on-restoring-immunotherapy-sensitivity-in-advanced-triple-negative-breast-cancer-using-ceralasertib-durvalumab-and-paclitaxel-albumin-bound/ This clinical trial is focused on studying a type of breast cancer known as advanced triple-negative breast cancer (TNBC). This form of cancer does not have the three common receptors known to fuel most breast cancer growth: estrogen, progesterone, and the HER2 protein. The study aims to explore the effectiveness of a treatment plan that includes a medication called ceralasertib, followed by a combination of two other medications, durvalumab and paclitaxel albumin-bound. Ceralasertib is taken in tablet form, while durvalumab and paclitaxel albumin-bound are given through an infusion, which means they are administered directly into the bloodstream.

The purpose of this study is to evaluate how well this treatment plan works for patients whose cancer has returned after previous treatments. The study will involve a period where participants will first receive ceralasertib to prepare their bodies, followed by the combination of durvalumab and paclitaxel albumin-bound. This approach is being tested to see if it can help restore the body’s sensitivity to immunotherapy, a type of treatment that uses the body’s immune system to fight cancer.

Participants in the study will be monitored over a period of time to assess the progression of their cancer and any responses to the treatment. The study will also track the overall health and survival of participants, as well as any side effects they may experience. The goal is to determine if this treatment plan can effectively control the cancer and improve the quality of life for those affected by advanced triple-negative breast cancer.

]]> Study of Pembrolizumab and Carboplatin for Patients with BRCA-Related Metastatic Breast Cancer https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-carboplatin-for-patients-with-brca-related-metastatic-breast-cancer/ Wed, 29 Apr 2026 14:57:58 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-carboplatin-for-patients-with-brca-related-metastatic-breast-cancer/ This clinical trial is focused on studying a type of breast cancer known as BRCA-related metastatic breast cancer. The study is investigating the effects of a treatment that combines two medications: Pembrolizumab and Carboplatin. Pembrolizumab, also known by its code name MK-3475, is a medication that helps the immune system fight cancer cells. Carboplatin is a chemotherapy drug that works by stopping the growth of cancer cells.

The purpose of this study is to evaluate how well this combination treatment works in patients with BRCA-related metastatic breast cancer. Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over a period of time, with regular visits to monitor the effects of the treatment and any changes in the cancer.

Throughout the study, doctors will assess the response of the cancer to the treatment using specific criteria to determine if the cancer is shrinking or staying the same. The goal is to understand the effectiveness of Pembrolizumab and Carboplatin in treating this type of breast cancer and to gather information that could help improve future treatments for patients with similar conditions.

]]> Study of Eftilagimod Alpha and Paclitaxel in Patients with HER2-Negative/Low Metastatic Breast Cancer https://clinicaltrials.eu/trial/study-of-eftilagimod-alpha-and-paclitaxel-in-patients-with-her2-negative-low-metastatic-breast-cancer/ Wed, 29 Apr 2026 14:28:04 +0000 https://clinicaltrials.eu/trial/study-of-eftilagimod-alpha-and-paclitaxel-in-patients-with-her2-negative-low-metastatic-breast-cancer/ This clinical trial is focused on studying a type of breast cancer known as HER2-negative/low metastatic breast cancer. The study is testing a new treatment called eftilagimod alpha, also known by its code name IMP321. This treatment is given as a solution for injection and is being tested in combination with a standard chemotherapy drug called paclitaxel. The trial also includes a comparison group that will receive paclitaxel with a placebo.

The purpose of the study is to determine if the combination of eftilagimod alpha and paclitaxel is more effective in improving overall survival compared to paclitaxel with a placebo. Initially, the study will focus on finding the best dose of eftilagimod alpha to use with paclitaxel. After this, the main part of the study will begin, where participants will be randomly assigned to receive either the eftilagimod alpha and paclitaxel combination or paclitaxel with a placebo. The study will monitor participants over a period of time to assess the safety and effectiveness of the treatment.

Participants in the study will receive regular injections and will be closely monitored by healthcare professionals. The study aims to provide valuable information on whether eftilagimod alpha can offer a new treatment option for patients with HER2-negative/low metastatic breast cancer. The trial is expected to continue until 2027, with the goal of improving treatment outcomes for patients with this type of breast cancer.

]]> Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ Wed, 29 Apr 2026 14:23:10 +0000 https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ This clinical trial is focused on studying advanced solid tumors, which are types of cancer that have spread beyond their original location and are difficult to treat. The trial will test a new treatment called DS-3939a, which is given as a solution through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein. The purpose of the study is to evaluate the safety and tolerability of DS-3939a and to see how well it works in treating these advanced cancers.

The study is divided into two parts. In the first part, participants will receive DS-3939a to assess its safety and how well it is tolerated by the body. In the second part, the study will continue to evaluate safety and also measure the treatment’s effectiveness at a recommended dose. This will involve looking at how the cancer responds to the treatment, which is known as the objective response rate. Participants may have different types of advanced cancers, including those of the lung, breast, ovary, and pancreas, among others.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups, laboratory tests, and imaging studies to track the progress of the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of DS-3939a.

]]>